Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: Is combination therapy the answer?

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 24-36

  Nguyen, Hien M ^a   Graber, Christopher J ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bactericidal agents; Combination treatment; Community acquired infections; MRSA

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOTRANSFERASE; ANTIBIOTIC AGENT; BACTERIAL TOXIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; LINEZOLID; METHADONE; METICILLIN; MINOCYCLINE; NAFCILLIN; OXACILLIN; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; PYRAZOLE DERIVATIVE; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BONE INFECTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMMUNICABLE DISEASE; DEVICE INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPIDEMIC; HOSPITAL INFECTION; HUMAN; INFECTIOUS ARTHRITIS; INFECTIOUS PNEUMONIA; LACTIC ACIDOSIS; LIVER TOXICITY; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MYALGIA; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PERITONITIS; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SOFT TISSUE INFECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77950345996     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp377     Document Type: Review

References (164)

1. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Burton DC, Edwards JR, Horan TC et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301: 727-36.
3. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-71.
4. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 2008; 46: 787-94.
5. Liu C, Graber CJ, Karr M et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis 2008; 46: 1637-46.
6. Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
7. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
8. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97.
9. Burlak C, Hammer CH, Robinson MA et al. Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection. Cell Microbiol 2007; 9: 1172-90.
10. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am 2009; 23: 17-34.
11. Stevens DL, Ma Y, Salmi DB et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202-11.
12. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus- an antibiotic enters obsolescence. Clin Infect Dis 2007; 44: 1543-8.
13. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 Suppl 1: S13-24.
14. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
15. Sader HS, Jones RN, Rossi KL et al. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother 2009; 64: 1024-8.
16. Fowler VG Jr, Sakoulas G, McIntyre LM et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190: 1140-9.
17. Sakoulas G, Moise PA, Rybak MJ. Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings? J Infect Dis 2009; 199: 1558-9.
18. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42 Suppl 1: S40-50.
19. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46 Suppl 5: S360-7.
20. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12 Suppl 1: 16-23.
21. Cui L, Iwamoto A, Lian JQ et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 428-38.
22. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46: 1492-502.
23. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
24. Skhirtladze K, Hutschala D, Fleck T et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50: 1372-5.
25. Cruciani M, Gatti G, Lazzarini L et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865-9.
26. Garazzino S, Aprato A, Baietto L et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet 2008; 47: 793-805.
27. Ahmed A, Jafri H, Lutsar I et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1999; 43: 876-81.
28. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 Suppl 1: S35-9.
29. Drew RH, Lu I, Joyce M et al. Lack of relationship between predicted area under the time-concentration curve/minimum inhibitory concentration and outcome in vancomycin-treated patients with Staphylococcus aureus bacteremia. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract A-1493. American Society for Microbiology, Washington, DC, USA.
30. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
31. Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-55.
32. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
33. Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
34. del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV et al. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33: 279-85.
35. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44: 1536-42.
36. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
37. Enoch DA, Bygott JM, Daly ML et al. Daptomycin. J Infect 2007; 55: 205-13.
38. Jevitt LA, Smith AJ, Williams PP et al. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist 2003; 9: 389-93.
39. Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.
40. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 3061-7.
41. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003; 348:86-7.
42. Palenzuela L, Hahn NM, Nelson RP Jr et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40: e113-6.
43. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27: 1189-97.
44. Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260-6.
45. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
46. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56: 923-9.
47. Wilcox MH, Tack KJ, Bouza E et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48: 203-12.
48. Jang HC, Kim SH, Kim KH et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49: 395-401.
49. Moellering RC Jr. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: 1032-7.
50. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfa-methoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-8.
51. de Gorgolas M, Aviles P, Verdejo C et al. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995; 39: 953-7.
52. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: 584-93.
53. Martinez-Aguilar G, Hammerman WA, Mason EO Jr et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593-8.
54. Geddes AM, Dwyer NS, Ball AP et al. Clindamycin in bone and joint infections. J Antimicrob Chemother 1977; 3: 501-7.
55. Ruhe JJ, Monson T, Bradsher RW et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40: 1429-34.
56. Florescu I, Beuran M, Dimov R et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 Suppl 1: i17-28.
57. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
58. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
59. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006; 26: 1099-110.
60. Wyeth Pharmaceuticals. Tygacilw (tigecycline) prescribing information. Philadelphia, PA.
61. Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Suppl A: 53-8.
62. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group. J Antimicrob Chemother 1999; 43: 783-92.
63. Diep BA, Chambers HF, Graber CJ et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148: 249-57.
64. Drew RH, Perfect JR, Srinath L et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46: 775-84.
65. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36: 473-81.
66. Eng RH, Smith SM, Buccini FJ et al. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J Antimicrob Chemother 1985; 15: 201-7.
67. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008; 27: 3-15.
68. Hageman JC, Liedtke LA, Sunenshine RH et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43: e42-5.
69. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ et al. Clinical Consensus Conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis 2009; 48 Suppl 4: S260-70.
70. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009; 49: 1072-9.
71. Perlroth J, Kuo M, Tan J et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168: 805-19.
72. Henry NK, Rouse MS, Whitesell AL et al. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82:73-5.
73. Norden CW, Shaffer M. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J Infect Dis 1983; 147: 352-7.
74. Zimmerli W, Frei R, Widmer AF et al. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 959-67.
75. Lucet JC, Herrmann M, Rohner P et al. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34: 2312-7.
76. Chuard C, Herrmann M, Vaudaux P et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991; 35: 2611-6.
77. Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985; 151: 157-65.
78. Hessen MT, Pitsakis PG, Kaye D. Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34: 1143-5.
79. Perdikaris G, Giamarellou H, Pefanis A et al. Vancomycin or vancomycin plus netilmicin for methicillin-and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob Agents Chemother 1995; 39: 2289-94.
80. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
81. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-41.
82. Saginur R, Stdenis M, Ferris W et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50: 55-61.
83. DeLeo FR, Otto M. An antidote for Staphylococcus aureus pneumonia? J Exp Med 2008; 205: 271-4.
84. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother 2007; 13: 141-6.
85. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2463-7.
86. Maor Y, Hagin M, Belausov N et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
87. Shelburne SA, Musher DM, Hulten K et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 2004; 48: 4016-9.
88. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350: 1422-9.
89. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364: 369-79.
90. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: 3167-84.
91. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97: 496-503.
92. Sande MA, Courtney KB. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J Lab Clin Med 1976; 88:118-24.
93. Watanakunakorn C, Baird IM. Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci 1977; 273: 133-9.
94. Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41: 2497-501.
95. Lee DG, Chun HS, Yim DS et al. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother 2003; 47: 3768-73.
96. Watanakunakorn C, Tisone JC. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1982; 22: 903-5.
97. Mulazimoglu L, Drenning SD, Muder RR. Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1534-5.
98. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-34.
99. Cosgrove SE, Vigliani GA, Fowler VG Jr et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48: 713-21.
100. Buchholtz K, Larsen CT, Hassager C et al. Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 2009; 48: 65-71.
101. Kang SL, Rybak MJ. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob Agents Chemother 1995; 39: 1505-11.
102. Kang SL, Rybak MJ. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Suppl A: 33-9.
103. Allen GP, Cha R, Rybak MJ. In vitro activities of quinu-pristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46: 2606-12.
104. Fuchs PC, Barry AL, Brown SD. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal. Antimicrob Agents Chemother 2001; 45: 2662-5.
105. Pavie J, Lefort A, Zarrouk V et al. Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics. Antimicrob Agents Chemother 2002; 46: 3061-4.
106. Scotton PG, Rigoli R, Vaglia A. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens. Infection 2002; 30: 161-3.
107. Sgarabotto D, Cusinato R, Narne E et al. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis 2002; 34: 122-6.
108. Moise PA, Forrest A, Paladino JA et al. Rapid response of methicillin-resistant Staphylococcus aureus infections to quinupristin-dalfopristin plus vancomycin in patients failing vancomycin [abstract]. Pharmacotherapy 2002; 22: 413.
109. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007; 60: 334-40.
110. Sakoulas G, Eliopoulos GM, Alder J et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1714-8.
111. Baltch AL, Ritz WJ, Bopp LH et al. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob Agents Chemother 2008; 52: 1829-33.
112. Nguyen HA, Denis O, Vergison A et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations. Antimicrob Agents Chemother 2009; 53: 1443-9.
113. Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-60.
114. Burdette SD. Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine. Spine J 2009; 9:e5-8.
115. Forrest GN, Donovan BJ, Lamp KC et al. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. Ann Pharmacother 2008; 42: 213-7.
116. Antony SJ. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 2006; 38: 293-5.
117. Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 2006; 38: 133-6.
118. Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007; 51: 1504-7.
119. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49: 2735-45.
120. DeRyke CA, Sutherland C, Zhang B et al. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother 2006; 50: 3529-34.
121. Thibault N, Grenier L, Simard M et al. Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob Agents Chemother 1994; 38: 1027-35.
122. Gurnani K, Khouri H, Couture M et al. Molecular basis of the inhibition of gentamicin nephrotoxicity by daptomycin; an infrared spectroscopic investigation. Biochim Biophys Acta 1995; 1237: 86-94.
123. Dailey CF, Pagano PJ, Buchanan LV et al. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2003; 47: 2655-8.
124. Jacqueline C, Caillon J, Le Mabecque V et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-64.
125. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 418-20.
126. Tsuji BT, Rybak MJ. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis 2006; 54:73-7.
127. Tsaganos T, Skiadas I, Koutoukas P et al. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 2008; 62: 381-3.
128. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27: 476-9.
129. Egle H, Trittler R, Kummerer K et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005; 77: 451-3.
130. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-72.
131. Jacqueline C, Asseray N, Batard E et al. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2004; 24: 393-6.
132. Jemni L, Hmouda H, Letaief A. Efficacy of trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus: a report from Tunisia. Clin Infect Dis 1994; 19: 202-3.
133. Sanchez C, Matamala A, Salavert M et al. Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection. Enferm Infecc Microbiol Clin 1997; 15:10-3.
134. Traub WH, Spohr M, Bauer D. Gentamicin-and methicillin-resistant Staphylococcus aureus: in vitro susceptibility to antimicrobial drugs. Chemotherapy 1987; 33: 361-75.
135. Kaka AS, Rueda AM, Shelburne SA III et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 680-3.
136. Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181: 7566-70.
137. Chambers HF, Sachdeva M. Binding of β-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis 1990; 161: 1170-6.
138. Palmer SM, Rybak MJ. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. J Antimicrob Chemother 1997; 39: 515-8.
139. Domaracki BE, Evans AM, Venezia RA. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother 2000; 44: 1394-6.
140. Leonard SN, Rice L. Synergy between vancomycin and nafcillin against heterogeneously glycopeptides intermediate Staphylococcus aureus (hGISA). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract E-1451. American Society for Microbiology, Washington, DC, USA.
141. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999; 43: 1747-53.
142. Domenech A, Ribes S, Cabellos C et al. Experimental study on the efficacy of combinations of glycopeptides and β-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2005; 56: 709-16.
143. Yanagisawa C, Hanaki H, Matsui H et al. Rapid depletion of free vancomycin in medium in the presence of β-lactam antibiotics and growth restoration in Staphylococcus aureus strains with β-lactam-induced vancomycin resistance. Antimicrob Agents Chemother 2009; 53:63-8.
144. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 2871-5.
145. Yang S, Jones T, Sawa A et al. Decreased daptomycin susceptibility in methicillin-resistant Staphylococcus aureus is commonly linked to increased oxacillin susceptibility. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract C2-142. American Society for Microbiology, Washington, DC, USA.
146. Dhand A, Wang G, Nizet V et al. Supplemental β-lactam rescue in clearance of bacteremia due to MRSA with reduced vancomycin and daptomycin susceptibility. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract C2-142. American Society for Microbiology, Washington, DC, USA.
147. Jacqueline C, Navas D, Batard E et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 45-51.
148. Jacqueline C, Caillon J, Grossi O et al. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 2547-9.
149. Li M, Diep BA, Villaruz AE et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci USA 2009; 106: 5883-8.
150. Dumitrescu O, Boisset S, Badiou C et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007; 51: 1515-9.
151. Dumitrescu O, Badiou C, Bes M et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008; 14: 384-8.
152. Gemmell CG. Antibiotics and the expression of staphylococcal virulence. J Antimicrob Chemother 1995; 36: 283-91.
153. Stevens DL. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 2000; 51: 271-88.
154. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167: 1401-5.
155. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. NEnglJMed2005; 352:1445-53.
156. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128: 2732-8.
157. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3002-4.
158. Booker BM, Stahl L, Smith PF. In vitro antagonism with the combination of vancomycin and clindamycin against Staphylococcus aureus. J Appl Res 2004; 4: 385-95.
159. Ho JL, Klempner MS. In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn Microbiol Infect Dis 1986; 4: 133-8.
160. Venditti M, Baiocchi P, Santini C et al. Potential of clindamycin in addition to vancomycin for the treatment of oxacillin-resistant Staphylococcus aureus septicemia persisting under vancomycin therapy. Int J Antimicrob Agents 1995; 5: 123-8.
161. Szabo J. hVISA/VISA: diagnostic and therapeutic problems. Expert Rev Anti Infect Ther 2009; 7:1-3.
162. Appelbaum PC. Time-Kill Activity of relavancin (TLV) alone and in combination against hVISA, VISA, and VRSA. In: Abstracts of the Forty-eighth Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting, Washington, DC, 2008. Abstract C1-3718, p. 133. American Society for Microbiology, Washington, DC, USA.
163. Belley A. Oritavancin (ORI) Combinations with linezolid (LIN) and nafcillin (NAF) are synergistic against vancomycin (VAN)-non-susceptible S. aureus. In: Abstracts of the Forty-eighth Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting, Washington, DC, 2008. Abstract C1-3720, p. 134. American Society for Microbiology, Washington, DC, USA.
164. Vidaillac C. In vitro activity and aminoglycoside synergy of ceftaroline (CPT) against clinical isolates of hospital-acquired (HA) methicillin-resistant Staphylococcus aureus (MRSA). In: Abstracts of the Forty-eighth Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting, Washington, DC, 2008. Abstract C1-3719, p. 134. American Society for Microbiology, Washington, DC, USA.